Loading…
← CockpitCompetitor Analysis › 002437.SZ Harbin Gloria Pharmaceuticals Co., Ltd. Class AOpen in the cockpit ↗

Harbin Gloria Pharmaceuticals Co., Ltd. Class A002437.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Harbin-based pharmaceutical manufacturer selling generic drugs in China.

Momentum neutral 43
Mkt cap
$941M
US dollars, full cap
Free float
78%
of shares outstanding
$/day
$62.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+7.2 pp
WACC 7.7%
Hurdle
+15 pp
Req g minus delivered
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥2.86
1D+0.7%
1W-6.8%
1M-9.8%
3M-32.7%
6M-9.2%
YTD-6.8%
1Y-15.9%
ATR %5.0%
52w lowhigh43.9% off high

What Harbin Gloria Pharmaceuticals does

Harbin-based pharmaceutical manufacturer selling generic drugs in China.

Where it sits in the supply chain

  • Pharmaceuticals
  • Generics

Moat: none

Headquarters: Harbin, China · Employees: 2,350

Harbin Gloria Pharmaceuticals at a glance

Size Harbin Gloria Pharmaceuticals (002437.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $941M, the 2269th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥2.86 on 18 Nov 2026.

Performance Over six months the shares fell 9.2%, against -22.0% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue fell 15.6% over the last twelve months (peer median +2.4%); the operating margin is 13.0% (peer median 7.1%).

Valuation It trades at 2.8× enterprise value to sales against a peer median of 4.5× (7th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is -7%, so the hurdle is +15 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 7.2 points above its cost of capital (7.7% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026002437.SZ 91Peer median 79
Six months, rebased to 100: Harbin Gloria Pharmaceuticals against the median of its 20 peers (local-currency closes).

Harbin Gloria Pharmaceuticals financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.90BCN¥2.12BCN¥2.42BCN¥2.60BCN¥3.07B
Revenue growth—-13%-7%-15%—
Gross profitCN¥915MCN¥929MCN¥1.27BCN¥1.49BCN¥2.32B
EBITDAn/aCN¥318MCN¥312MCN¥275MCN¥230M
Net incomeCN¥381MCN¥377MCN¥233MCN¥120M-CN¥291M
Free cash flowCN¥246MCN¥291MCN¥360MCN¥251MCN¥245M
Capital expenditureCN¥19.4MCN¥23.8MCN¥62.9MCN¥29.6MCN¥33.0M
Total debtCN¥107MCN¥136MCN¥107MCN¥675MCN¥1.45B

Quarterly statements and history in the cockpit →

Harbin Gloria Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%600422603538600252STAR20056881770392003004013002946887591795MLTXIMTX25954565688553PGHLSPTX688382002437.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Harbin Gloria Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%0×25×50×75×6004226035386002526881770392001795IMTX2595600129688382002437.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Harbin Gloria Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

-50%-25%0%+25%-50%0%603538600252STAR200503920030040117954565688553PGHL688382002437.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Harbin Gloria Pharmaceuticals is the large dot.

Harbin Gloria Pharmaceuticals competitors and peer comparison

How Harbin Gloria Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Harbin Gloria Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure002437.SZPeer medianRank in peer set
1-month return-9.8%-9.4%11th highest of 21
6-month return-9.2%-22.0%6th highest of 21
Distance from 52-week high-43.9%-46.9%10th highest of 21
Revenue growth (TTM)-15.6%+2.4%7th lowest of 18
Operating margin13.0%7.1%7th highest of 18
EV / Sales2.8×4.5×7th cheapest of 18
Growth the price implies (Req g, 7 yrs)7.7%9.1%6th least demanding of 12
Growth delivered (Del g)-6.9%+7.8%3rd lowest of 12
Hurdle (Req g minus delivered)+14.7 pp+2.8 pp4th most demanding of 12
ROIC minus cost of capital+7.2 pp-2.0 pp3rd highest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Harbin Gloria Pharmaceuticals 002437.SZChina$941M-9%-16%13%2.8×7.7%-6.9%
KPC Pharmaceuticals 600422.SSChina$940M-6%-41%-10%1.8×n/an/a
Ningbo Menovo Pharmaceutical 603538.SSChina$945M-48%+19%9%3.8×11.6%+4.9%
Guangxi Wuzhou Zhongheng 600252.SSChina$936M-10%-43%-42%4.5×10.3%-13.7%
Strides Pharma Science STAR.NSIndia$946M-17%+11%14%2.0×17.6%+7.8%
SSY 2005.HKHong Kong$948M+8%-4%12%2.2×2.3%-0.5%
Bio-Thera Solutions 688177.SSChina$929M-23%+24%-44%6.5×n/an/a
Oscotec 039200.KSSouth Korea$923M-32%+510%59%7.5×-10.2%+18.1%
Zhejiang Garden Biopharmaceutical 300401.SZChina$922M-14%+2%24%5.2×9.1%+13.4%
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%2.5×n/an/a
BeBetter Med 688759.SSChina$960M-58%n/an/an/an/an/a
Lotus Pharmaceutical 1795.TWTaiwan$921M-37%+67%21%2.6×-3.7%+13.8%
MoonLake Immunotherapeutics MLTXUnited States$918M-37%n/an/an/an/an/a
Immatics IMTXUnited States$913M-46%-44%-589%8.5×n/an/a
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%55.9×n/an/a
Nxera Pharma 4565.TJapan$974M+46%+24%14%5.4×17.7%+27.3%
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%3.5×19.4%-6.0%
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%6.3×5.6%+9.3%
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a
Chongqing Taiji Industry (Group) 600129.SSChina$982M-20%-4%2%1.3×n/an/a
InventisBio 688382.SSChina$982M-47%-61%-563%75.0×6.5%-60.6%

Questions

Which companies are Harbin Gloria Pharmaceuticals's closest peers?
The cockpit's peer set: KPC Pharmaceuticals (600422.SS), Ningbo Menovo Pharmaceutical (603538.SS), Guangxi Wuzhou Zhongheng (600252.SS), Strides Pharma Science (STAR.NS), SSY (2005.HK), Bio-Thera Solutions (688177.SS), Oscotec (039200.KS), Zhejiang Garden Biopharmaceutical (300401.SZ).
Is Harbin Gloria Pharmaceuticals expensive compared with its peers?
On ev / sales it trades at 2.8× against a peer median of 4.5×, 7th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is -7%, so the hurdle is +15 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Harbin Gloria Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -9.2% against -22.0% for the median peer; over one year -15.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.